The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer. Abdollahi A, Favata M, Weber M, Roman V, et al. PLoS One 2025;20:e0327588.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Abdollahi A, Favata M, Weber M, Roman V, et al. The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer. PLoS One 2025;20:e0327588.
PMID: 40788860